Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Orion Corporation, Orion Pharma
• Treatments: Simendan

Criteria

Inclusion Criteria:

• Three vessel coronary artery disease.

• Indication for on-pump coronary artery bypass surgery.

• Ejection fraction below 50%

Exclusion Criteria:

• Indication for any cardiac valve surgery

• Previous coronary artery bypass surgery